Clindamycin in Prosthetic Joint Infections Caused by Staphylococcus (CISTA)

Regional University Hospital Center (CHRU)

Status: Unknown

Conditions: Prosthetic Joint Infection; Staphylococcus

Study type: Observational

Funder types: Other

Identifiers

NCT04946500

CISTA - 29BRC21.0123

Details and patient eligibility

About

The alternatives to the combination of Fluoroquinolone and Rifampicin in prosthetic joint infections (PJI) caused by staphylococcus are currently unclear. Clindamycin is prescribed as dual therapy in this indication, and provides many advantages. We conducted a multicenter retrospective observational study evaluating the efficacy and safety of Clindamycin in prosthetic joint infections due to staphylococcus between January 2013 and December 2019.

Enrollment: 120 estimated patients

Sex: All

Ages: 18 to 120 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Patients with PJI defined according to the IDSA.
• Infection must be mono-microbial or multi-microbial with Staphylococcus spp sensitive to Clindamycin.
• Infection may be acute or chronic, nosocomial or community-acquired.
• Patient having received a curative treatment with Clindamycin.

Exclusion criteria

• Patients with osteitis, osteomyelitis, septic arthritis in native joints, diabetic foot infections, spondylodiscitis, infections in external fixator, surgical site infections following neurosurgical management, bedsores, skin and soft tissue infections.
• Patients with mono-microbial infections other than Staphylococcus, multi-microbial infections including other bacteria than Staphylococcus, suspected Osteoarticular Infection without microbial identification.
• Patients with clindamycin-resistant Staphylococcal PJI, constitutive MLSb phenotype.
• Patients having received suspensive treatment with Clindamycin.
• Patients treated with Clindamycin as last line of treatment for a duration of less than 14 days.
• Patients refusing to participate
• Patients under legal protection (guardianship, curatorship, ..)

Trial design

120 participants in 2 patient groups

Clindamycin and Rifampicin

Description:

Patients treated with Clindamycin and Rifampicin

Clindamycin and Fluoroquinolone

Description:

Patients treated with Clindamycin and Fluoroquinolone